Work

Efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.e15123

Authors: Tao Zhang, Zhenyu Lin, Lei Zhao, Hong Ma, Dejun Zhang, Dandan Yu, Min Jin, Jing Wang, Hongli Liu

Institutions: Wuhan Union Hospital, Huazhong University of Science and Technology

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399325784

Cites:

Cited by:

Related to: 10